New imaging test aids Alzheimer's diagnosis

August 23, 2012 in Alzheimer's disease & dementia

New imaging test aids Alzheimer’s diagnosis

Enlarge

The image on the left is a PET scan of a normal brain. The image on the right is heavily blackened throughout the cerebral cortex due to the the presence of amyloid plaques. Amyloid is found in the brains of patients with dementia due to Alzheimer’s disease

In research studies, scientists regularly use positron emission tomography (PET) scans to detect signs of Alzheimer's disease. Now, Washington University physicians at Barnes-Jewish Hospital are the first in Missouri to offer a new type of PET scan for patients with memory disorders and other forms of cognitive impairment who are not involved in research studies.

This new imaging test is now available to patients being evaluated for Alzheimer's disease because the U.S. (FDA) recently approved the use of a radioactive diagnostic agent, Amyvid™ (Florbetapir F 18 Injection), for use in a clinical setting.

The agent detects neuritic plaques, a hallmark of Alzheimer's disease, by binding to abnormal deposits of the protein beta-amyloid that develop in the brains of patients with the disorder. This makes the plaques "light up" during a PET scan.

This video is not supported by your browser at this time.

"We're using the scans in patients whose cognitive function is impaired," says Farrokh Dehdashti, MD, professor of radiology in the Division of Nuclear Medicine at the Mallinckrodt Institute of Radiology. "First, the patient sees a neurologist, or other specialist in cognitive disorders, to confirm that a test like this would be appropriate, and then we conduct the to learn whether are present. In that way, the test allows both doctors and patients to have a better idea of whether the patient's is related to Alzheimer's disease or some other illness."

With , nuclear medicine specialists like Dehdashti can now use the diagnostic agent, which has a longer half-life than the compound used in research studies, making it better suited for clinical use. As a single test, PET scans can't confirm Alzheimer's disease, but a negative test that finds no evidence of elevated beta-amyloid can help rule out the disease as the cause for the patient's cognitive impairment.

"What complicates the results of a scan is that although Alzheimer's disease is very common, it's not the only reason that we might detect amyloid," according to Jonathan McConathy, MD, PhD, assistant professor of radiology. "A positive scan could mean that a person has Alzheimer's disease, or it could be related to some other neurologic disorder. It's also possible to find amyloid in the brain of a person who has no symptoms of Alzheimer's disease or other cognitive problems, so a positive test doesn't confirm that someone has the disease."

He says a positive scan indicates only that elevated levels of amyloid are present. But amyloid plaques can accumulate in the brains of people with other types of neurologic problems, such as dementia with Lewy bodies or cerebral amyloid angiopathy. Plaques also can occur in some older adults who are cognitively normal.

"The test should be used in conjunction with other diagnostic evaluations from a neurologist," Dehdashti says. "But when a scan is negative, it's highly unlikely that the cognitive impairment is due to Alzheimer's disease."

"These PET scans have the potential to be really useful as treatments for Alzheimer's are developed," McConathy says. "Once we have treatments to significantly slow down or stop the progression of Alzheimer's , then I think this kind of imaging will become very important in deciding who should be treated and, potentially, whether a treatment is working."

Washington University in St. Louis search and more info website

5 /5 (1 vote)  

Rank 5 /5 (1 vote)
Relevant PhysicsForums posts

More news stories

Drugs found to both prevent and treat Alzheimer's disease in mice

Researchers at USC have found that a class of pharmaceuticals can both prevent and treat Alzheimer's Disease in mice.

Alzheimer's disease & dementia created May 21, 2013 | popularity 5 / 5 (7) | comments 0 | with audio podcast

Scientists identify molecular trigger for Alzheimer's disease

Researchers have pinpointed a catalytic trigger for the onset of Alzheimer's disease – when the fundamental structure of a protein molecule changes to cause a chain reaction that leads to the death of neurons ...

Alzheimer's disease & dementia created May 20, 2013 | popularity 5 / 5 (4) | comments 0 | with audio podcast

Study finds that sleep apnea and Alzheimer's are linked

A new study looking at sleep-disordered breathing (SDB) and markers for Alzheimer's disease (AD) risk in cerebrospinal fluid (CSF) and neuroimaging adds to the growing body of research linking the two.

Alzheimer's disease & dementia created May 19, 2013 | popularity 5 / 5 (3) | comments 0 | with audio podcast

Alzheimer's leaves bilingual victims stranded in Canada

The devastating effect of Alzheimer's disease on bilingual people has been thrown into focus in Canada, where the sudden loss of a second language can leave sufferers feeling like strangers in their own country.

Alzheimer's disease & dementia created May 19, 2013 | popularity not rated yet | comments 0

Study identifies new approach to improving treatment for MS and other conditions

(Medical Xpress)—Working with lab mice models of multiple sclerosis (MS), UC Davis scientists have detected a novel molecular target for the design of drugs that could be safer and more effective than current FDA-approved ...

Alzheimer's disease & dementia created May 17, 2013 | popularity 5 / 5 (2) | comments 0 | with audio podcast


Fecal microbiota tx feasible for recurrent C. difficile in HIV

(HealthDay)—For HIV-infected individuals with recurrent Clostridium difficile infection, fecal microbiota therapy is feasible, according to a letter published in the May 21 issue of the Annals of Intern ...

Systematic screening of med adherence will ID barriers

(HealthDay)—Implementation of systematic monitoring for medication adherence will allow for identification of barriers to adherence and tailoring of interventions, according to a viewpoint piece published ...

FDA panel backs experimental Merck insomnia drug

(AP)—A federal panel of medical experts says that an experimental insomnia drug from Merck & Co Inc. appears safe and effective, despite evidence from company trials that the pill can cause daytime sleepiness and difficulty ...

American cancer society celebrates 100 years of progress

(HealthDay)—The American Cancer Society, which is celebrating on Wednesday a century of fighting a disease once viewed as a death sentence, is making a pledge to put itself out of business.

Having both migraines, depression may mean smaller brain

(HealthDay)—Migraines and depression can each cause a great deal of suffering, but new research indicates the combination of the two may be linked to something else entirely—a smaller brain.

Brain can be trained in compassion, study shows

Until now, little was scientifically known about the human potential to cultivate compassion—the emotional state of caring for people who are suffering in a way that motivates altruistic behavior.